Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated

Open access
Wong, Michelle M Y, Tu, Charlotte, Li, Yun, Perlman, Rachel L, Pecoits-Filho, Roberto, Lopes, Antonio A, Narita, Ichiei, Reichel, Helmut, Port, Friedrich K, Sukul, Nidhi, Stengel, Benedicte, Robinson, Bruce M, Massy, Ziad A, Pisoni, Ronald L, the CKDopps Investigators, Combe, Christian, Jacquelinet, Christian, Ayav, Carole, Briançon, Serge, Fouque, Denis, Frimat, Luc, Laville, Maurice, Pascal, Christophe, Herpe, Yves-Edouard, Lange, Céline, Legrans, Karine, Liabeuf, Sophie, Metzger, Marie, Speyer, Elodie, Combe, Christian, Jacquelinet, Christian, Ayav, Carole, Briançon, Serge, Fouque, Denis, Frimat, Luc, Laville, Maurice, Pascal, Christophe, Herpe, Yves-Edouard, Lange, Céline, Legrans, Karine, Liabeuf, Sophie, Metzger, Marie, Speyer, Elodie · 2020 · Clinical Kidney Journal

Abstract

Background: International variation in anemia assessment and management practices in chronic kidney disease (CKD) is poorly understood. Methods: We performed a cross-sectional analysis of anemia laboratory monitoring, prevalence and management in the prospective Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps). A total of 6766 participants with CKD Stages 3a–5ND from nephrology clinics in Brazil, France, Germany and the USA were included. Results: Among patients with anemia (hemoglobin <12 g/dL), 36–58% in Brazil, the USA and Germany had repeat hemoglobin measured and 40–61% had iron indices measured within 3 months of the index hemoglobin measurement. Anemia was more common in the USA and Brazil than in France and Germany across CKD stages. Higher ferritin and lower iron saturation (TSAT) levels were observed with lower hemoglobin levels, and higher ferritin with more advanced CKD. The proportion of anemic patients with ferritin <100 ng/mL or TSAT <20% ranged from 42% in Brazil to 53% in France and Germany, and of these patients, over 40% in Brazil, Germany and the USA, compared with 27% in France, were treated with oral or intravenous iron within 3 months after hemoglobin measurement. The proportion of patients with hemoglobin <10 g/dL treated with erythropoiesis-stimulating agents ranged from 28% in the USA to 57% in Germany. Conclusions: Hemoglobin and iron stores are measured less frequently than per guidelines. Among all regions, there was a substantial proportion of anemic patients with iron deficiency who were not treated with iron, highlighting an area for practice improvement in CKD care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ckj/sfz091

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Cumulative incidence of hemoglobin measurement. (a) By CKD stage. (b) By hemoglobin level. Graph by CKD stage allows patients to contribute once for each stage. French data are excluded from the graph as the laboratory measurements are collected according to a predefined study protocol. Time 0 is the first hemoglobin (Hgb) measurement. KDIGO 2012 anemia guidelines [21]: (i) for nondialysis CKD patients with anemia not being treated with an ESA, hemoglobin should be measured when clinically indicated and at least every 3 months in patients with CKD Stages 3–5ND; (ii) for nondialysis CKD patients being treated with an ESA, hemoglobin should be measured at least monthly during the initiation phase of ESA therapy, whereas hemoglobin should be measured at least every 3 months during the maintenance phase of ESA therapy.
FIGURE 1 Cumulative incidence of hemoglobin measurement. (a) By CKD stage. (b) By hemoglobin level. Graph by CKD stage allows patients to contribute once for each stage. French data are excluded from the graph as the laboratory measurements are collected according to a predefined study protocol. Time 0 is the first hemoglobin (Hgb) measurement. KDIGO 2012 anemia guidelines [21]: (i) for nondialysis CKD patients with anemia not being treated with an ESA, hemoglobin should be measured when clinically indicated and at least every 3 months in patients with CKD Stages 3–5ND; (ii) for nondialysis CKD patients being treated with an ESA, hemoglobin should be measured at least monthly during the initiation phase of ESA therapy, whereas hemoglobin should be measured at least every 3 months during the maintenance phase of ESA therapy.CC BY-NC · PubMed Central
FIGURE 2 Measurement of iron parameters, by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Measurement within ±3 months from hemoglobin (Hgb) value. French data are excluded from the graph as the laboratory measurements are collected according to a predefined study protocol.
FIGURE 2 Measurement of iron parameters, by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Measurement within ±3 months from hemoglobin (Hgb) value. French data are excluded from the graph as the laboratory measurements are collected according to a predefined study protocol.CC BY-NC · PubMed Central
FIGURE 3 Hemoglobin distribution, by country and CKD stage. Patients could contribute once for each CKD stage experienced during the study for (a). First hemoglobin (Hgb) for each stage was taken if there were multiple measures.
FIGURE 3 Hemoglobin distribution, by country and CKD stage. Patients could contribute once for each CKD stage experienced during the study for (a). First hemoglobin (Hgb) for each stage was taken if there were multiple measures.CC BY-NC · PubMed Central
FIGURE 4 Serum ferritin distribution, by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Ferritin values within ±3 months from hemoglobin (Hgb) value.
FIGURE 4 Serum ferritin distribution, by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Ferritin values within ±3 months from hemoglobin (Hgb) value.CC BY-NC · PubMed Central
FIGURE 5 TSAT distribution, by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). TSAT values within ±3 months from hemoglobin (Hgb) value.
FIGURE 5 TSAT distribution, by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). TSAT values within ±3 months from hemoglobin (Hgb) value.CC BY-NC · PubMed Central
FIGURE 6 Iron (Fe) status, by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Ferritin and TSAT values within ±3 months from hemoglobin value in (b).
FIGURE 6 Iron (Fe) status, by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Ferritin and TSAT values within ±3 months from hemoglobin value in (b).CC BY-NC · PubMed Central
FIGURE 7 Prescription of ESAs and iron (oral or IV), by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Prescription within 3 months subsequent to hemoglobin measurement. Graph by CKD stage allows patients to contribute once for each stage. ESA = Erythropoiesis-stimulating agent.
FIGURE 7 Prescription of ESAs and iron (oral or IV), by country. (a) By CKD stage. (b) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Prescription within 3 months subsequent to hemoglobin measurement. Graph by CKD stage allows patients to contribute once for each stage. ESA = Erythropoiesis-stimulating agent.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. 2012, KDIGO clinical practice guideline for anemia in chronic kidney disease, Kidney Int Suppl, 2, 279

Cited by

See all 140

Metadata

Authors
Wong, M. M. Y., Tu, C., Li, Y., Perlman, R. L., Pecoits-Filho, R., Lopes, A. A., Narita, I., Reichel, H., Port, F. K., Sukul, N., Stengel, B., Robinson, B. M., Massy, Z. A., Pisoni, R. L., the CKDopps Investigators, Combe, C., Jacquelinet, C., Ayav, C., Briançon, S., Fouque, D., Frimat, L., Laville, M., Pascal, C., Herpe, Y.-E., Lange, C., Legrans, K., Liabeuf, S., Metzger, M., Speyer, E., Combe, C., Jacquelinet, C., Ayav, C., Briançon, S., Fouque, D., Frimat, L., Laville, M., Pascal, C., Herpe, Y.-E., Lange, C., Legrans, K., Liabeuf, S., Metzger, M., & Speyer, E.
Affiliations
  • University of British Columbia (CA)
  • Arbor Research Collaborative for Health (US)
  • University of Michigan (US)
  • Department of Medicine, University of British Columbia, Vancouver, BC, Canada
  • Universidade Federal da Bahia (BR)
  • Niigata University (JP)
  • Nephrologisches Zentrum Villingen-Schwenningen (DE)
  • CESP, Center for Research in Epidemiology and Population Health, Univ Paris-Saclay, Univ Paris-Sud, UVSQ, Inserm UMRS 1018, Villejuif, France
  • Inserm (FR)
Corresponding author
Wong, Michelle M Y
Venue
Clinical Kidney Journal
Published
2019-08-03
Volume
13
Issue
4
Pages
613-624
ISSN
  • 2048-8505 (ISSN-L)
  • 2048-8513
OpenAlex
W2964863420
Cited by
140
References
49
Citations by year
2026: 20 · 2025: 24 · 2024: 18 · 2023: 19 · 2022: 20 · 2021: 22 · 2020: 16 · 2019: 1
FWCI
10.43
Type
journal article
Language
en
Open access
Locations
  • Clinical Kidney Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
DOPPS Programs
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Keywords
anemia of chronic kidney disease, iron deficiency, hemoglobin monitoring, ferritin, transferrin saturation, iron supplementation, erythropoiesis-stimulating agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. https://app.cochat.ai/papers/10.1093/ckj/sfz091
The paper
Wong, M. M. Y., Tu, C., Li, Y., Perlman, R. L., Pecoits-Filho, R., Lopes, A. A., Narita, I., Reichel, H., Port, F. K., Sukul, N., Stengel, B., Robinson, B. M., Massy, Z. A., Pisoni, R. L., the CKDopps Investigators, Combe, C., Jacquelinet, C., Ayav, C., Briançon, S., . . . Speyer, E. (2020). Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfz091

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.